CBO Overestimates Costs Of Enforcing DXM Sales Age-Restriction – CHPA
This article was originally published in The Tan Sheet
Executive Summary
CHPA says CBO's five-year $232m estimate for the costs of compliance with the DXM Abuse Prevention Act is too high since it is based on costs of FDA's tobacco compliance check program. CBO says the bill would have a minimal cost impact on retailers, since many already restrict sales.
You may also be interested in...
US Would Cough Up As Much As $31bn More For Rx-Only DXM Over 10 Years
A study the Consumer Healthcare Products Association commissioned finds OTC access to the cough suppressant dextromethorphan will save consumers between $22bn and $31bn through 2025 compared to a scenario of the product moving to Rx-only.
US Would Cough Up As Much As $31bn More For Rx-Only DXM Over 10 Years
A study the Consumer Healthcare Products Association commissioned finds OTC access to the cough suppressant dextromethorphan will save consumers between $22bn and $31bn through 2025 compared to a scenario of the product moving to Rx-only.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.